Jin Yu Tan
Associate, Singapore
Biography
Overview
Jin Yu Tan is an associate in the Mergers & Acquisitions and Private Equity practice, based in Singapore.
Jin Yu advises private equity sponsors, sovereign wealth funds, government pension funds, family offices and strategic clients on a variety of matters across multiple sectors, including acquisitions, divestitures, venture financing, growth equity investments, PIPEs and other corporate transactions.
Prior to joining White & Case, Jin Yu worked in the Hong Kong office of a leading global law firm.
Bars and Courts
Registered Foreign Lawyer, The Law Society of Hong Kong
Singapore Bar
Education
LLB
National University of Singapore
Languages
English
Mandarin
Experience
Jin Yu's experience* includes representation of:
- SoftBank Vision Fund in the US$2.4 billion Series D and D+ financing (alongside Tencent and Sequoia Capital China) of Beike, a leading PRC real estate brokerage platform.
- Advent International in the sale of its controlling interest in AI Dream, a leading premium sleep solution provider that operates global brands Serta and King Koil in China.
- Jio Platforms Limited, a subsidiary of Reliance Industries Limited, in its proposed US$200 million Series D investment in Glance, a leading AI-driven lock-screen platform.
- Apax Funds in their acquisition of the software products business of 3i Infotech Limited (NSE: 3IINFOTECH), an Indian IT solutions company listed on the National Stock Exchange of India Limited.
- Partners Group (SIX: PGHN) in the sale of various assets in the technology sector in the Southeast Asia region.
- Blackstone in its US$150 million investment in 21Vianet Group, Inc. (NASDAQ: VNET), a leading carrier- and cloud-neutral Internet data center services provider in the PRC.
- An investor consortium, comprising Centurium Capital, PW Medtech Group Limited (HKSE: 1358), CITIC Capital, Temasek and Marc Chan, in the take-private of China Biologic Products Holdings, Inc. (NASDAQ: CBPO), a leading fully integrated plasma-based biopharmaceutical company in China, at a valuation of approximately US$4.6 billion. This transaction was named "Pharmaceuticals, Medical and Biotech M&A Deal of the Year" by Mergermarket China M&A Awards 2021, "2021 Deals of the Year" by China Business Law Journal and "M&A Deal of the Year" by China Law & Practice Awards 2021.
- Sino-Ocean Prime Office Partners I LP, a US$1.4 billion fund formed by Sino-Ocean Capital, on the acquisition of Ocean Office Park and Project Z6, two grade-A office projects located in the central business district of Beijing.
- Clermont Group in its US$76 million investment in Eviation Aircraft, an Israeli electric aircraft company.
- TPG in various transactions (including its acquisition of Novotech).
- A sovereign wealth fund in its investment in a US$300 million credit fund focusing on investments in the US and European structured credit markets.
- Macquarie Infrastructure and Real Assets (MIRA) in its establishment of a real estate investment platform with Greystar Real Estate Partners, LLC and APG Asset Management N.V., focusing on high-quality rental housing in Asia-Pacific.
*Includes matters prior to joining White & Case.
